2018 Bevyxxa Drug Analysis Report: Approved in the US for the Prophylaxis of VTE in Adult Patients Hospitalized for an Acute Medical Illness - ResearchAndMarkets.com

DUBLIN--()--The "Drug Analysis: Bevyxxa" drug pipelines has been added to ResearchAndMarkets.com's offering.

Drug Overview

Bevyxxa (betrixaban; Portola Pharmaceuticals) is approved in the US for the prophylaxis of VTE in adult patients hospitalized for an acute medical illness. It is currently the only anticoagulant approved for extended use in both hospital and out-patient settings. The medication is an oral, once-daily factor Xa inhibitor. By directly inhibiting factor Xa, Bevyxxa reduces thrombin generation, thrombus formation, and thrombin-induced platelet aggregation, thus preventing blood clots.

Key Topics Covered:

Product Profiles

Bevyxxa: Venous thromboembolism (VTE)

List of Figures

Figure 1: Bevyxxa for venous thromboembolism - SWOT analysis

Figure 2: Drug assessment summary of Bevyxxa for venous thromboembolism

Figure 3: Drug assessment summary of Bevyxxa for venous thromboembolism

List of Tables

Table 1: Bevyxxa drug profile

Table 2: Bevyxxa pivotal trial data in venous thromboembolism

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/cc3c2s/2018_bevyxxa_drug?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Hematological Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Hematological Drugs